News

Aspivix mentioned in Swissquote article about FemTech

March 1, 2022

Share this story:

More from our blog

Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

Read More about Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

ASPIVIX Receives CE Mark Approval for Carevix™

Read More about ASPIVIX Receives CE Mark Approval for Carevix™

Welcoming Excellence to Aspivix’s Board: Dr. Susan Nicholson and Jessica J. Federer

Read More about Welcoming Excellence to Aspivix’s Board: Dr. Susan Nicholson and Jessica J. Federer

Aspivix CEO Mathieu Horras Discusses How Much IUD Insertion Can Hurt Less on X-Health.show

Read More about Aspivix CEO Mathieu Horras Discusses How Much IUD Insertion Can Hurt Less on X-Health.show

Aspivix mentioned in MD+DI – “Removing the Pain from ‘Just a Little Pinch’ Gynecological Procedures”

Read More about Aspivix mentioned in MD+DI – “Removing the Pain from ‘Just a Little Pinch’ Gynecological Procedures”

Aspivix Featured in Forbes France Following Top 10 Placement at Inaugural MedFemTech Congress

Read More about Aspivix Featured in Forbes France Following Top 10 Placement at Inaugural MedFemTech Congress

ASPIVIX Announces That Contraception, an International Reproductive Health Journal, Has Published First-In-Women Results Using Novel Cervical Stabilizer In IUD Procedures

Read More about ASPIVIX Announces That Contraception, an International Reproductive Health Journal, Has Published First-In-Women Results Using Novel Cervical Stabilizer In IUD Procedures

Aspivix receives U.S. FDA 510(k) Clearance for Carevix™, Their Novel Cervical Stabilizer

Read More about Aspivix receives U.S. FDA 510(k) Clearance for Carevix™, Their Novel Cervical Stabilizer

Aspivix mentioned in Femtech World about Serie A

Read More about Aspivix mentioned in Femtech World about Serie A

ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.

Read More about ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.